Targeting Urothelial Carcinoma
The U.S. FDA approved an antibody-drug conjugate to treat urothelial cancer, the most common form of bladder cancer. The...
Progress Against Cancer
The U.S. FDA approved an antibody-drug conjugate to treat urothelial cancer, the most common form of bladder cancer. The...
The U.S. FDA approved a new chemotherapy as part of a multi-drug regimen for certain patients with two similar...
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain...
The FDA has granted accelerated approval to a molecularly targeted therapeutic along with a companion diagnostic to treat certain...
The FDA granted accelerated approval to the first targeted therapeutic and a companion diagnostic for certain adult patients with...
The FDA has approved an immunotherapeutic for certain patients with these cancers who had their cancer completely resected and...
The FDA has granted accelerated approval to an immunotherapeutic to be used in combination with a targeted therapeutic and...
The FDA has approved the targeted therapeutic loncastuximab tesirine-lpyl to treat certain adult patients with large B-cell lymphoma. The...
The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction...